Skip to main content

Table 3 Acylcarnitine profile of the patient before and after riboflavin treatment

From: Patient with multiple acyl-CoA dehydrogenase deficiency disease and ETFDH mutations benefits from riboflavin therapy: a case report

Analytes Results Reference range Units
Before After
C0- Free carnitine 36 42 17–64 umol/L
C2- Acetylcarnitine 10 3 2-17 umol/L
C3-Propionylcarnitine 0.42 0.31 0.14–0.95 umol/L
C3DC-Malonylcarnitine 0.03 0.03 0.01–0.08 umol/L
C4-n-butyryl−/isobutyrylcarnitine 0.33 0.16 0.08–0.46 umol/L
C4OH-3-Hydroxy-Butyrylcarnitine 0.12 0.06 0.01–0.24 umol/L
C5-Isovaleryl−/2-Methylbutyrylcarnitine 0.39 0.10 0.03–0.32 umol/L
C5:1-Tiglylcarnitine 0.02 0.01 0.01–0.04 umol/L
C5OH-3-Hydroxy-Isovaerylcarnitine 0.03 0.03 0.01–0.09 umol/L
C5DC-Glutaryl/3-Hydroxydecanoylcarnitine 0.28 0.06 0.010.08 umol/L
C6-Hexanoylcarnitine 0.43 0.25 0.02–0.12 umol/L
C8-Octanoylcarnitine 1.50 1.69 0.03–0.22 umol/L
C10-Decanoylcarnitine 3.07 1.82 0.05–0.42 umol/L
C10:1-Decenoylcarnitine 0.40 0.61 0.03–0.26 umol/L
C10:2-Decadienoylcarnitine 0.05 0.05 0.01–0.05 umol/L
C12-Dodecanoylcarnitine 0.87 0.15 0.02–0.13 umol/L
C12:1-Dodecenoylcarnitine 0.13 0.09 0.01–0.10 umol/L
C14-Tetradecanoylcarnitine 0.51 0.05 0.01–0.07 umol/L
C14:1-Tetradecenoylcarnitine 0.72 0.15 0.01–0.17 umol/L
C14:2-Tetradecadienoylcarnitine 0.20 0.07 0.01–0.05 umol/L
C16-Hexadecanoylcarnitine 0.81 0.13 0.06–0.24 umol/L
C16:1-Hexadecenoylcarnitine 0.53 0.05 0.01–0.07 umol/L
C18-Octadecanoylcarnitine 0.34 0.04 0.02–0.10 umol/L
C18:1-Octadecenoylcarnitine 0.95 0.12 0.05–0.28 umol/L
C18:2-Linoleylcarnitine 0.33 0.05 0.02–0.10 umol/L
C16OH-3-Hydroxy-Hexadecanoylcarnitine 0.02 0.01 0.00–0.02 umol/L
  1. Numbers out of reference range are in bold